Theravance Biopharma Revenue, Profits - TBPH Annual Income Statement

Add to My Stocks
$29.94 $0.1 (0.34%) TBPH stock closing price Oct 12, 2018 (Closing)

TBPH stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Theravance Biopharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the TBPH stock is bound to reflect the impact of the YOY decline of -68.38%. The operating expenses as shown in the Theravance Biopharma profit and loss statement for 2017 total to $269.47M. This line item shows that the operating expenses has increased compared with last year. Also check: Theravance Biopharma assets and Theravance Biopharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Theravance Biopharma Revenues or Net Sales
15.38M48.64M42.12M11.68M-130.14M14.85M
Cost Of Goods Sold (COGS)6.03M2.89M4.65M4.05M---
Theravance Biopharma Gross Profit
9.35M45.75M37.46M7.63M-130.14M14.85M
Research & Development Expense173.88M141.71M129.16M168.52M120.57M113.99M98.85M
Selling General & Admin Expense95.59M84.5M90.2M71.64M35.93M25.72M25.33M
Income Before Depreciation Depletion Amortization-260.12M-180.46M-181.89M-232.53M-156.28M-9.57M-109.33M
Depreciation Depletion Amortization-------
Non Operating Income-3.04M1.31M-1.86M---
Interest Expense8.54M1.4M-----
Theravance Biopharma Pretax Income
-271.71M-180.55M-181.26M-230.67M-156.28M-9.57M-109.33M
Provision for Income Taxes13.69M10.11M-6.36M---
MinorityInterest-------
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations-285.4M-190.66M-182.21M-237.03M-156.28M-9.57M-109.33M
Extraordinary Items & Discontinued Operations-------
Theravance Biopharma Profit/ Loss (Net Income)
-285.4M-190.66M-182.21M-237.03M-156.28M-9.57M-109.33M
Average Shares used to compute Diluted EPS52.35M44.71M34.15M31.76M31.74M--
Average Shares used to compute Basic EPS52.35M44.71M34.15M31.76M31.74M--
Income Before Nonrecurring Items-285.41M-190.67M-182.22M-237.04M-156.28M--
Income from Nonrecurring Items-------
Theravance Biopharma Earnings Per Share Basic Net
-5.45-4.26-5.34-7.46-4.92--
Theravance Biopharma Earnings Per Share Diluted Net
-5.45-4.26-5.34-7.46-4.92--
EPS Diluted Before Nonrecurring Items-5.45-4.26-5.34-7.46-4.92--
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on Theravance Biopharma stock analysis. It helps to look at the following income statement items:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Theravance Biopharma revenue chart implies that the company is growing. It has not been the case with Theravance Biopharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-285.4M for Theravance Biopharma for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The TBPH financials along with Theravance Biopharma historical stock prices provide a lot of details about the firm.

Theravance Biopharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
39.67
Dividend Yield
0%

Annual Income Statements - Theravance Biopharma Inc Industry Peers

Merck income statement, Pacira Pharma income statement, Pfizer income statement, Ignyta income statement